Aydogdu, IOzturan, OKuku, IKaya, ESevinc, AYildiz, R2024-08-042024-08-0420001120-009Xhttps://doi.org/10.1179/joc.2000.12.6.530https://hdl.handle.net/11616/93270Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.eninfo:eu-repo/semantics/closedAccessmultiple myelomavincristinehearing losstoxicityBilateral transient hearing loss associated with vincristine therapy: Case reportArticle1265305321115403910.1179/joc.2000.12.6.5302-s2.0-0034520588Q3WOS:000166156600015Q3